Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- A-zas Looks to Offer E-Detailing App, Big-Data Analyses to More Firms
December 2, 2014
- Pralia Captures Top Spot in GP Market in October “Mind Share” Ranking
December 2, 2014
- Eisai Upgrades China to Independent Region with New Holding Firm
December 2, 2014
- Ferring to Launch Japan’s 1st Progestational Hormone Agent in ART Program on Dec. 5
December 2, 2014
- Eisai Files Lenvatinib for Approval in South Korea
December 2, 2014
- MTPC, Sawai Ink Final Pact on Transfer of Kashima Plant in April
December 2, 2014
- Daiichi Sankyo, UCB to Jointly Commercialize Epilepsy Drug Lacosamide
December 1, 2014
- Nippon Kayaku Rolls Out Remicade Biosimilar
December 1, 2014
- Novartis to Launch Stalevo Combination Tablets on Dec. 8
December 1, 2014
- Takeda to Transform Osaka Plant into Specialty Manufacturing Site for Leuplin
December 1, 2014
- Sandoz Launches Biosimilar of G-CSF Product Gran; Comarkets with Sawai
December 1, 2014
- Mochida Applies for Additional Indication of Social Anxiety Disorder for Lexapro
December 1, 2014
- EPS Gives 400 Workers CDISC Training to Set Itself Apart from Rival CROs
November 28, 2014
- MSD, Kyorin to Comarket Allergy Drug Desloratadine in Japan
November 28, 2014
- Novartis Files for Japan Approval of Equa-Metformin Combination Drug
November 28, 2014
- Kyowa Kirin Launches Sustained-Duration G-CSF Product G-Lasta
November 28, 2014
- Daiichi Sankyo Aims for No. 1 with Lixiana in Novel Oral Anticoagulant Market: Sales Division Head
November 28, 2014
- Allergan Targeting 10 Billion Yen Sales for GlashVista in Japan Eyelash Care Market
November 28, 2014
- ASKA Aims for 50% Share of Generic Candesartan Market through Blopress AG: President
November 27, 2014
- Janssen Files NDA for Anticancer Agent Ibrutinib in Japan
November 27, 2014
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…